ACP-101
Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure
Acadia Pharmaceuticals; Prader-Willi syndrome; carbetocin; ACP-101; phase 3 trial; hyperphagia; clinical trial failure; Soleno Therapeutics; Vykat XR
Actionable Insights Powered by AI
Acadia Pharmaceuticals; Prader-Willi syndrome; carbetocin; ACP-101; phase 3 trial; hyperphagia; clinical trial failure; Soleno Therapeutics; Vykat XR